Salt-Inducible Kinase as a Predictive Biomarker in Laryngeal Squamous Cell Carcinoma: Insights into Treatment Efficacy and Patient Survival
Nigerian Journal of Clinical Practice · 2026
DOI: 10.4103/njcp.njcp_341_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nigerian Journal of Clinical Practice, 2026. Verfasst von A F Gharib und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Biomarkers, Tumor, Carcinoma, Squamous Cell, Protein Serine-Threonine Kinases. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aim: Laryngeal squamous cell carcinoma (LSCC) is a challenging malignancy that requires effective treatment strategies and reliable biomarkers. This study aimed to evaluate the efficacy of induction chemotherapy (IC), followed by chemoradiotherapy in LSCC and to explore the potential of salt-inducible kinase 1 (SIK1) as a diagnostic and prognostic biomarker.
Methods
A total of 108 patients with locally advanced LSCC were treated with IC, followed by definitive radiotherapy. Treatment responses were assessed, and SIK1 expression levels were analyzed in tumor and adjacent normal tissues (ANT) using quantitative real-time polymerase chain reaction. The association between SIK1 expression and clinicopathological factors, treatment outcomes, and survival was evaluated.
Results
IC achieved a complete response (CR) rate of 29.6%, a partial response (PR) rate of 50%, and a stable disease rate of 20.4%. Following chemoradiotherapy, the CR rate increased to 74.4%. SIK1 expression was significantly lower in tumor tissues than in ANT ( P < 0.0001) and correlated with age, sex, performance status, tumor grade, stage, and treatment response (all P < 0.0001). Higher SIK1 expression was associated with improved overall survival and disease-free survival rates.
Conclusion
The combination of IC and chemoradiotherapy demonstrated promising tumor control and laryngeal preservation in patients with LSCC. SIK1 has emerged as a potential diagnostic and prognostic biomarker, with its expression levels correlating with key clinicopathological factors and survival outcomes. These findings highlight the need for further investigation into the clinical and mechanistic roles of SIK1 in LSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
- Department of Biochemistry, Faculty of Pharmacy, Sinai University, El-Arish, Saudi Arabia.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
- Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
- Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Zitieren
APA
Gharib, A. F., Bakhuraysah, M. M., Alrehaili, A. A., Alharthi, A., Alsalmi, O., Hawsawi, N. M., Aljohani, A. I., Elkashef, K. A., Atteia, H., & Elsawy, W. H. (2026). Salt-Inducible Kinase as a Predictive Biomarker in Laryngeal Squamous Cell Carcinoma: Insights into Treatment Efficacy and Patient Survival. Nigerian Journal of Clinical Practice. https://doi.org/10.4103/njcp.njcp_341_25
Vancouver
Gharib AF, Bakhuraysah MM, Alrehaili AA, Alharthi A, Alsalmi O, Hawsawi NM, et al. Salt-Inducible Kinase as a Predictive Biomarker in Laryngeal Squamous Cell Carcinoma: Insights into Treatment Efficacy and Patient Survival. Nigerian Journal of Clinical Practice. 2026. doi:10.4103/njcp.njcp_341_25
BibTeX
@article{Gharib2026,
author = {Gharib, A F and Bakhuraysah, M M and Alrehaili, A A and Alharthi, A and Alsalmi, O and Hawsawi, N M and Aljohani, A I and Elkashef, K A and Atteia, Hhm and Elsawy, W H},
title = {Salt-Inducible Kinase as a Predictive Biomarker in Laryngeal Squamous Cell Carcinoma: Insights into Treatment Efficacy and Patient Survival},
journal = {Nigerian Journal of Clinical Practice},
year = {2026},
doi = {10.4103/njcp.njcp_341_25}
}
EUVIMED